Fisher & Paykel Healthcare Corporation Limited (FPH) is a New Zealand-based global leader in the design, manufacture, and marketing of innovative products and systems for respiratory and acute care, as well as the treatment of obstructive sleep apnea. Operating within the critical medical instruments and supplies sector, FPH's core mission is to ensure that patients, whether in a hospital ICU or the comfort of their own home, can breathe with optimal comfort and efficacy. Their technology meticulously conditions the air, adjusting temperature and humidity to physiological levels, thereby fundamentally shaping the quality of each inhalation and exhalation for those relying on their devices. In essence, they are the unseen engineers behind every vital, humidified gasp and sigh, making them indispensable to modern healthcare.

The company’s extensive product portfolio includes respiratory humidifiers, breathing circuits, chambers, masks, nasal cannulas, and Continuous Positive Airway Pressure (CPAP) devices, alongside infant resuscitators and warmers for neonatal care. Their business model thrives on a relentless pursuit of product innovation, backed by substantial R&D investments—approximately 10% of revenue—and a formidable intellectual property arsenal boasting over 2,000 patents worldwide. This commitment to innovation, coupled with significant manufacturing scale in New Zealand and Mexico, grants them a dominant market share in respiratory humidifiers and a strong position in sleep apnea treatment. They distribute globally through a hybrid model of direct sales teams and a network of distributors, reaching over 120 countries, with North America, Europe, and Asia-Pacific being key markets.

FPH’s competitive advantages are robust, stemming from high switching costs for healthcare providers due to specialized training and patient care continuity, and highly differentiated products that demonstrably improve patient outcomes. While generally a quiet achiever, the company has navigated its share of drama, including a protracted global patent dispute with competitor ResMed, which was finally settled in 2019, proving that even life-saving breath can be a battleground. More recently, in October 2026, FPH disclosed a cyber incident involving unauthorized access to employee email accounts and company files containing personally identifiable information, though thankfully, no patient data systems were compromised, and operations remained uninterrupted.